Clinical Trial

Adjuvant Palbociclib in Elderly Patients With Breast Cancer

Study acronym: Appalaches
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Phase II study to assess the efficacy of the combination of at least 5 year endocrine therapy and 2 year-palbociclib as adjuvant systemic treatment instead of adjuvant chemotherapy followed by endocrine therapy in older patients with stage II-III ER+/HER2- early breast cancer.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2018-07-31; most recent amendment 2026-05-07.
Status change: Recruiting → Active, Not Recruiting 2022-11-16
Status change: Not Yet Recruiting → Recruiting 2019-06-20
Trial Details
NCT Number NCT03609047
Lead Sponsor European Organisation for Research and Treatment of Cancer - EORTC
Collaborators: Pfizer, Swedish Association of Breast Oncologists, ETOP IBCSG Partners Foundation, German Adjuvant Breast Cancer Group, SOLTI Breast Cancer Research Group, UNICANCER, Gruppo Oncologico Italiano di Ricerca Clinica, Breast International Group
Conditions Breast Cancer Stage II, Breast Cancer Stage III
Enrollment 366 participants
Start Date 2019-06-14
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-12